Table 1.
Patients’ demographic and clinical characteristics
| Patients no | Sex | Age year | ECOG | History of tobacco use | Histologic type | cTNM | Stage | PD-L1 (TPS %) | Neoadjuvant therapy | Cycle |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 54 | 0 | Former | A | T4N2M0 | IIIB | – | Pemetrexed + carboplatin + Sintilimab | 4 |
| 2 | M | 58 | 0 | Current | S | T3N1M0 | IIIA | – | Abraxane + cisplatin + Sintilimab | 2 |
| 3 | M | 50 | 0 | Current | S | T3N2M0 | IIIB | 1% | Abraxane + carboplatin + Sintilimab | 3 |
| 4 | M | 58 | 0 | Former | S | T3N2M0 | IIIB | – | Abraxane + cisplatin + Sintilimab | 3 |
| 5 | M | 58 | 0 | Current | A | T4N2M0 | IIIB | – | Pemetrexed + cisplatin + Sintilimab | 4 |
| 6 | M | 56 | 0 | Former | NSCLC | T3N2M0 | IIIB | – | Abraxane + carboplatin + Sintilimab | 4 |
| 7 | M | 68 | 0 | Former | S | T4N0M0 | IIIA | 2% | Taxol + carboplatin + Sintilimab | 3 |
| 8 | M | 53 | 0 | Former | S | T2N2M0 | IIIA | 8% | Abraxane + cisplatin + Sintilimab | 4 |
| 9 | F | 59 | 0 | Never | A | T2N2M0 | IIIA | – | Abraxane + carboplatin + Sintilimab | 3 |
| 10 | M | 68 | 0 | Former | S | T2N1M0 | IIB | < 1% | Taxol + cisplatin + Sintilimab | 2 |
| 11 | M | 67 | 0 | Former | S | T3N0M0 | IIB | 60% | Abraxane + cisplatin + Sintilimab | 2 |
| 12 | M | 53 | 0 | Former | S | T4N0M0 | IIIA | 10% | Taxol + cisplatin + Sintilimab | 4 |
| 13 | M | 65 | 0 | Former | S | T3N2M0 | IIIB | 60% | Taxol + carboplatin + Sintilimab | 3 |
F female, M male, ADC adenocarcinoma, SCC squamous carcinoma, cTNM clinical TNM stage